ONKOLOGIYADA GEN TERAPIYASINING ISTIQBOLLARI
Keywords:
gen terapiyasi, onkologiya, CRISPR, virusli vektorlar, CAR-T, immunoterapiya, klinik tadqiqotlar.Abstract
Gen terapiyasi so‘nggi yillarda onkologiyada keng tadqiq qilinayotgan istiqbolli yo‘nalishlardan biriga aylandi. U o‘sma hujayralarini molekulyar darajada nishonga olish imkonini beradi. Ushbu adabiyotlar sharhida gen terapiyasining asosiy prinsiplari, turli vektorlar orqali genlarni etkazish usullari, klinik tadqiqotlar, CRISPR/Cas9 texnologiyasi va immunoterapiya bilan kombinatsiyalangan yondashuvlar yoritilgan. Shuningdek, gen terapiyasining cheklovlari va xavfsizlik jihatlari ham ko‘rib chiqildi. Tadqiqotlar ushbu terapiya usulining individual onkologik davolashda keng qo‘llanilish istiqbolini tasdiqlamoqda.
References
1. American Cancer Soceity. 1973-1999 Annual Reports.
2. Abakumova O.Yu., Podobed O.V., Tsvetkova T.A., Yakusheva I.V., Moskvitina T.A., Kondakova L.I., Navasardyantz D.G., Medvedev A.E. J. Neural. Transm. Suppl; 52:87-91, 1998.
3. Andtbacka RH, et al. Talimogene laherparepvec improves durable response rate. J Clin Oncol. 2015
4. Bartlett J.S. et al. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F (ab' gamma)2 antibody. NatBiotechnol, 171: 181-186, 1999.
5. Cloughesy TF, et al. First-in-human trial of Toca 511 and Toca FC. Neuro Oncol. 2018
6. Doudna JA, Charpentier E. The new frontier of genome engineering. Science. 2014
7. Dunbar CE, et al. Gene therapy comes of age. Science. 2018
8. Fousek K, et al. CAR T-cells for solid tumors: new strategies. Front Immunol. 2021
9. Ginn SL, et al. Gene therapy clinical trials worldwide. J Gene Med. 2018
10. Hacein-Bey-Abina S, et al. Insertional oncogenesis in gene therapy. Science. 2003
11. Hollon T. Researchers and regulations on first gene therapy death. Nat. Med. 6 (6), 2000.
12. June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018
13. Karle P., Renner M., Salmons В., Gunzburg W.H. Necrotic rather than apoptotic cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther., 8 (3): 220-230, 2001.
14. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016
15. Naldini L. Gene therapy returns to centre stage. Nature. 2015
16. Niidome T, Huang L. Gene therapy progress and prospects. Gene Ther. 2002
17. Peng Z. Current status of Gendicine in China. Curr Opin Mol Ther. 2005
18. Promega. Transfection guide. Pp.60. 1999.
19. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018
20. Roth J.A. Gene therapy for cancer. Am. Cancer Soc., 37: 1234-1245, 1999.
21. Sylvius R., Leventis J.R. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim. Biophys. Acta, v.1023 (1): 124-132, 1997.
22. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors. Nat Rev Genet. 2003
23. Templeton N.S., basic D.D. New directions in liposome gene delivery. Mol Biotechnol.; v. 11 (2): 175-180, Apr, 1999.
24. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005.
25. Wiethoff C.M., Gill M.L., Кое G.S., Кое J.G., Middaugh C.R. The structural organization of cationic lipid/DNA complexes. J. Biol. Chem. 2002 Sep 23; v.140, p.567-580, 2002.26. basic D. D. Liposomes in Gene Delivery, CRC Press, Boca Raton, FL, 1997.